Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:02:50 2024-04-25 pm EDT			5-day change	1st Jan Change
130.7 ^USD	+2.93%		+4.38%	+19.90%

Apr. 25	Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating	MT
Apr. 25	Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	MT

Merck & Co., Inc. Provides Earnings Guidance for the Year 2022

April 28, 2022 at 06:30 am EDT

Merck & Co., Inc. provided earnings guidance for the year 2022. For the year, the company expects Sales in the range of $56.9 to $58.1 billion, and EPS in the range of $5.90 to $6.02.

Latest news about Merck & Co., Inc.

Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating	Apr. 25	MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
The specter of stagflation rears its ugly head again	Apr. 25
Transcript : Merck & Co., Inc., Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat	Apr. 25	MT
Merck raises annual target ranges	Apr. 25	CF
Merck Non-GAAP Earnings, Sales Rise; 2024 Guidance Raised	Apr. 25	MT
(MRK) MERCK & CO. Expects Fiscal Year 2024 EPS Range $8.53 - $8.65	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Reports Q1 Revenue $15.78B	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Posts Q1 EPS $2.07	Apr. 25	MT
Merck & Co., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024	Apr. 25	CI
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales	Apr. 25	RE
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Hipgnosis' bidding war intensifies as Concord hikes offer for Shakira music owner	Apr. 25	RE
Hanmi Pharmaceutical Enters into Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. to Evaluate BH3120 in Combination with KEYTRUDA®? (pembrolizumab)	Apr. 23	CI
Merck Says Health Canada Approved Keytruda Plus Fluoropyrimidine, Platinum-Containing-Chemotherapy for Gastric Cancer	Apr. 19	MT
BMO Capital Adjusts Price Target on Merck & Company to $148 From $132	Apr. 19	MT
Leerink Partners Raises Merck's Price Target to $134 From $129	Apr. 19	MT
Zacks Adjusts Price Target on Merck & Company to $132 From $128	Apr. 15	MT
Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust	Apr. 11	CI
Merck & Co Receives a Shareholder Proposal from National Legal and Policy Center	Apr. 11	CI
Merck & Co Receives a Shareholder Proposal from Kenneth Steiner	Apr. 11	CI
Transcript : Merck & Co., Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024 09:55 AM	Apr. 11

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

Pharmaceuticals

Calendar

2024-05-28 - Annual General Meeting

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

130.7 USD

Average target price

137.6 USD

Spread / Average Target

+5.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MERCK & CO., INC.	+19.90%	322B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B
SANOFI	+2.07%	117B

Other Pharmaceuticals

Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Merck & Co., Inc. Provides Earnings Guidance for the Year 2022

Latest news about Merck & Co., Inc.

Chart Merck & Co., Inc.

Company Profile

Income Statement Evolution

Ratings for Merck & Co., Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals